#EPIRESEHA
LightNews LightNews
salmantongarcia.bsky.social
🚨 Metapneumovirus (#hMPV) causes severe disease in hem_onc patients, with ICU admission and mortality rates comparable to influenza and COVID-19. Yet it remains largely overlooked.

🎥 Watch our @vumediid.bsky.social presentation based on the #EPICOVIDEHA registry:

www.vumedi.com/video/human-...
Human Metapneumovirus (hMPV) Outcomes in Patients With Hematologic Malignancies: Insights From the EPICOVIDEHA/EPIRESEHA Registry
A video from Jon Salmanton-García, posted on Jun 3, 2026.
www.vumedi.com
June 5, 2026 at 8:58 AM
salmantongarcia.bsky.social
Seeing our research become one of the most read in @AjHematology is incredibly moving. This recognition belongs to the entire #EPICOVIDEHA-EPIRESEHA network! 🩺✨

Your interest gives true meaning to our scientific work.

🔗 onlinelibrary.wiley.com/doi/10.1002/...

@olivercornely.bsky.social
May 25, 2026 at 12:11 PM
id-journal.bsky.social
hMPV in 130 hematologic pts (58.5y, 57%♂): 64%🏥, 19%ICU, 8% 30-day⬇️. Risk⬆️ with renal dz (HR 20.9). Severity like flu/SARS-CoV-2 but less tx.🦠
Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA Registry
Human metapneumovirus (hMPV) is an increasingly recognized respiratory pathogen in immunocompromised patients, but its impact in haematological malignancies is poorly defined. Unlike influenza or SARS-CoV-2, hMPV has no specific treatment or vaccine, contributing to underdiagnosis and underestimation of its clinical relevance.MethodWe performed a multicentre retrospective cohort study within the Epidemiology of COVID-19 in patients with hematological malignancies: A European Haematology Association Survey/ Epidemiology of respiratory viral infections in patients with hematological malignancies: A European Haematology Association Survey registry of haematological patients with hMPV (January 2023–December 2024), comparing clinical features and outcomes with matched influenza and SARS-CoV-2 cohorts.ResultsThe study included 130 patients with hMPV. Median age was 58.5 years; 57% were male. Plasma cell neoplasms (25%), lymphoma (23%), and acute myeloid leukemia (20%) were the most common hematological malignancies. Hospitalization occurred in 64%, intensive care unit (ICU) admission in 19%, and 30-day mortality was 8%. Most cases (73%) received supportive care only. Secondary infections were common (24%). Chronic renal disease significantly increased mortality risk (hazard ratio 20.9 11.05, P = .014). Compared with influenza and SARS-CoV-2, hMPV patients had comparable severity and outcomes, with 18.5% ICU admission rates versus 25.9% for influenza (P = .316) and 20.9% versus 4.7% for SARS-CoV-2 (P = .006), and 30-day mortality of 5.6% versus 11.1% for influenza (P = .489) and 7.0% versus 2.3% for SARS-CoV-2 (P = .277), yet received fewer targeted interventions.ConclusionshMPV causes clinically significant disease in patients with hematological malignancy, often necessitating hospital and ICU care, and leading to mortality. In the absence of specific treatments or vaccines, this virus remains an underrecognized pathogen in patients with hematological malignancy. Enhanced clinical awareness and investment in diagnostics, prevention, and therapeutics are needed.
academic.oup.com
March 20, 2026 at 3:00 AM
olivercornely.bsky.social
🎥 New data on #hMPV in patients with hematologic malignancies: @salmantongarcia.bsky.social highlights how the lack of prophylaxis & treatment increases hospitalizations, ICU needs, and mortality.
Watch now: youtu.be/1EsYHcRQZ8g
Publication: doi.org/10.1093/ofid...
#Hematology #InfectiousDiseases
hMPV in Hematologic Malignancies: Key Insights from EPICOVIDEHA/EPIRESEHA
YouTube video by IDIM IDIM
youtu.be
March 4, 2026 at 11:35 AM
salmantongarcia.bsky.social
youtu.be/1EsYHcRQZ8g?...
March 4, 2026 at 10:35 AM
olivercornely.bsky.social
RSV poses high risk in adults with hematological malignancies. Study highlights the urgent need for higher vaccination coverage, faster diagnostics & improved therapies to reduce hospitalizations, secondary infections and mortality. Read: onlinelibrary.wiley.com/doi/10.1002/...
Beyond the Usual Suspects: RSV Infection in Patients With Hematological Malignancies Compared to Influenza and SARS‐COV‐2—A Report From the EPICOVIDEHA/EPIRESEHA Registry
Click on the article title to read more.
onlinelibrary.wiley.com
January 27, 2026 at 10:18 AM
alexxxmd.bsky.social
Beyond the Usual Suspects: RSV Infection in Patients With Hematological Malignancies Compared to Influenza and SARS‐COV‐2—A Report From the EPICOVIDEHA/EPIRESEHA Registry
Jon Salmanton-García, et al.
doi.org/10.1002/ajh....
December 24, 2025 at 7:21 PM
salmantongarcia.bsky.social
Today in Rome 🇮🇹, at #LaboratorioSEIFEM, we discussed #hMPV and #RSV in hematology patients

Still looking for cases of viral respiratory infections 🦠 of any kind within #EPICOVIDEHA / #EPIRESEHA 🧬

Always a pleasure to exchange ideas with our Italian colleagues! 🇮🇹
November 11, 2025 at 11:24 AM
salmantongarcia.bsky.social
🧬 COVID showed us the importance of viral vigilance—but respiratory infections go far beyond it.

Catch the latest EPICOVIDEHA-EPIRESEHA webinar on influenza, RSV, hMPV and more:

youtu.be/C2LTcEDnAoI?...
EPIRESEHA Webinar: Insights and Perspectives on Viral Respiratory Infections
YouTube video by IDIM IDIM
youtu.be
October 29, 2025 at 12:54 PM
olivercornely.bsky.social
Viral respiratory infections are often underestimated in hematology. Watch our #EPIRESEHA webinar with experts on influenza, RSV, hMPV & more: youtu.be/C2LTcEDnAoI
#Hematology #InfectiousDiseases
EPIRESEHA Webinar: Insights and Perspectives on Viral Respiratory Infections
YouTube video by IDIM IDIM
youtu.be
October 29, 2025 at 12:24 PM
salmantongarcia.bsky.social
SAVE THE DATE

📅 Oct 22, 2025 | 16:00 CET | #EPIRESEHA: Insights and perspectives on viral #respiratory_infections

F. Marchesi, IT – #Influenza
J. Salmanton-García, DE – #RSV
M. Biernat, PL – #hMPV
B. Weinbergerova, CZ – #Other_viruses

uni-koeln.zoom.us/meeting/register/r0LvqJ95QNWZuYhJXbUAIg
October 9, 2025 at 6:32 AM
olivercornely.bsky.social
Looking forward to chairing the #EPIRESEHA Webinar on Oct 22, 16:00–18:00 CEST 🦠 Together with Livio Pagano, we’ll discuss #RSV, #Influenza, #hMPV & more in hematology with outstanding speakers. Join us! 👉 uni-koeln.zoom.us/meeting/regi...
October 1, 2025 at 10:47 AM
salmantongarcia.bsky.social
📢 Join us on 22 Oct 2025, 16:00–18:00 CEST for the #EPIRESEHA Webinar: Insights on Viral Respiratory Infections!

🦠 Explore #RSV, #influenza, #hMPV and more in hematology with experts

@olivercornely.bsky.social @salmantongarcia.bsky.social

Register 👉 uni-koeln.zoom.us/meeting/regi...
September 30, 2025 at 12:43 PM